"kindness?"

"Although the companies with the highest offer may be the most interested, it does not mean that they have the strongest execution capabilities." Gris said: "A suitable company may only take two or three years to complete the clinical trial of deferrosterone. An inappropriate company may take seven or eight years..."

"I understand, I will choose the most suitable company, even if it doesn't make money." Yang Ruiyi said righteously.

"How could it be that you don't make money?" Grace glanced at him and said, "I am the only medicine chemist in your team, and you don't have a salary. The total development time is no more than three months. Even if you add the time for your theoretical research, there is not much cost. You will become a Monopoly."

"That's not bad." Yang Rui laughed out loud.

...

the next day.

Van Lunding also made a similar scream: "The Chinese are really going to get rich."

Arnold also said calmly: "54 points are indeed a score to get rich."

What they do is evaluate clinical drug candidates, which is to evaluate a drug with a high chance of passing clinical experiments.

Only by passing drugs with high chances can one enter clinical candidates and then have the opportunity to conduct clinical trials.

Unlike ordinary people's intuition, those drugs that may be effective in treating diseases do not have strong advantages in clinical drug candidate evaluation. The reason is very simple. There are many good drugs. If you can pass the review, you will make money. What you cannot pass is just a rainbow.

Any drug that gets a high score in the evaluation of clinical drug candidates means that there is great prospects. Companies like Gerrycon and Pfizer like the most is to acquire drugs after the animal experiment stage.

They will spend tens of millions or hundreds of millions of yuan to purchase a drug, and then spend two or three times the price to conduct clinical trials. Once they are successfully passed, they can earn back all their previous efforts in one go.

It is also for this reason that three-quarters of the original drugs developed by countries around the world every year are developed on the targets of existing drugs.

Although such original medicines are also original, they are not very original, but they are very safe.

They are cash cows that can make profits safely.

The more extreme example is the antidepressant SSRIS, which has approved no less than 7 products, and each has received sales of more than $1 billion.

In any pharmaceutical company, "blockbusters" are important capital, so they are hard to come by. In contrast, it is much easier to make an original drug with the target of SSRIS.

Deferrosterone is different because the last seven active substances left by Yang Rui have good effect and their scores are very high, which greatly increases the chance of deferrosterone passing clinical trials.

As long as it can pass clinical trials and go public, how to sell it is another matter.

According to Jielikan's evaluation model, compounds with a score of more than 30 can usually be included in the list of clinical candidate drugs. They are basically at the top of the list of above 40 points. If there is no major problem, clinical trials will definitely be conducted.

As for drugs with a score of more than 50, there are not necessarily a few drugs every year.

Arnold also calculated and then confirmed that the deferrosterone reached the 54-point standard.

"This guy has applied for so complete patents." Arnold didn't know whether he was impressed or angry.

If there is an opportunity, big pharmaceutical companies don't mind looting small companies by snatching patents.

For a drug with annual sales of over 100 million yuan and worth over 1 billion or even 10 billion yuan, large pharmaceutical companies can do anything.

Frankie personally inspected the patent and said: "Yang Rui is still suing for PCR now, so he must be very concerned about the patent issue."

"I registered the patents for intermediates, preparation methods, product patents, crystal patents, amorphous patents, and composition patents in one go!" Arnold said with his teeth: "He is too insecure, so he can't give people a little more trust."

Franky thought about the "trust" issue for a long time.
Chapter completed!